Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Halozyme Therapeutics (HALO) PT Lowered to $19 at BMO Capital
November 7, 2018 9:00 AM ESTBMO Capital analyst Do Kim lowered the price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $21.00) while maintaining a Market Perform rating.
The analyst commented, "We expect HALO shares to remain range bound until PEGPH20 Phase 3 PFS data in 1H19, unless a... More
